Liu Weiming, Ni Ming, Jia Wang, Zhou Dabiao, Zhang Qing, Jiang Yong, Jia Guijun
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
World Neurosurg. 2015 Aug;84(2):283-291.e1. doi: 10.1016/j.wneu.2015.03.013. Epub 2015 Mar 17.
Small- and medium-sized acoustic neuromas (ANs) increase in both number and proportion. Observation, radiosurgery, and microsurgery are all used to treat this disease; however, the appropriate treatment is controversial, especially in patients with hearing.
We searched the MEDLINE, EMBASE, CENTRAL (Cochrane Central Register of Con-trolled Trials), LILACS (Latin American and Caribbean Center on Health Sciences Information), and CMB (Chinese Biomedical Database) databases without limits on the language and the time of publication. For the wait-and-scan strategy, we included the population-based prospective studies with sufficient follow-up time and information. We also attempted to locate high-level evidence that compared radiosurgery with microsurgery. The data were extracted from the studies to synthesize the probabilities. We surveyed 60 patients with small- and medium-sized ANs to plot the outcomes on a linear scale to measure the utility.
Eight studies met the inclusion criteria of the wait-and-scan strategy, and 3 grade II evidence studies were found that compared microsurgery with radiosurgery. After synthesizing the data in 3 groups, the preservation of useful hearing was 58.9%, 60.2%, and 4.3%, whereas the rate of tumor control was 71.1%, 97.0%, and 94.3%, respectively. The expected value for radiosurgery was 0.68, whereas the expected values for wait-and-scan and surgery were 0.64 and 0.28, respectively.
On the basis of the evidence, radiosurgery is the optimal choice for small- and medium-sized ANs. Because of the current difficulty with understanding the natural history of ANs, we suggest that there is a need for new evidence and a health economics assessment to update this result.
中小型听神经瘤(AN)的数量和比例均有所增加。观察、放射外科手术和显微外科手术都用于治疗这种疾病;然而,合适的治疗方法存在争议,尤其是对于有听力的患者。
我们检索了MEDLINE、EMBASE、CENTRAL(Cochrane对照试验中心注册库)、LILACS(拉丁美洲和加勒比卫生科学信息中心)和CMB(中国生物医学数据库)数据库,对语言和发表时间均无限制。对于等待观察策略,我们纳入了有足够随访时间和信息的基于人群的前瞻性研究。我们还试图查找比较放射外科手术和显微外科手术的高级别证据。从研究中提取数据以综合概率。我们调查了60例中小型听神经瘤患者,以线性尺度绘制结果以衡量效用。
八项研究符合等待观察策略的纳入标准,发现三项II级证据研究比较了显微外科手术和放射外科手术。在将三组数据综合后,有用听力保留率分别为58.9%、60.2%和4.3%,而肿瘤控制率分别为71.1%、97.0%和94.3%。放射外科手术的期望值为0.68,而等待观察和手术的期望值分别为0.64和0.28。
基于现有证据,放射外科手术是中小型听神经瘤的最佳选择。由于目前难以了解听神经瘤的自然病程,我们建议需要新的证据和卫生经济学评估来更新这一结果。